Orphan Drug Safety: FDA Asks How Much Pre-Approval Data Is Enough?
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency's Advisory Committee for Pharmaceutical Science and Clinical Pharmacology will be asked to weigh pre-approval data requirements and discuss innovative approaches to boosting drug development for rare diseases at its March 2 meeting.